Immunic, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; comparative figures are for the year ended December 31, 2021. Immunic is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its principal programs are vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Product-sales revenue | None | None |
| Research and development expense | $71.3 million | $61.1 million |
| General and administrative expense | $15.3 million | $13.3 million |
| Total operating expenses | $119.5 million | $91.7 million |
| Net loss | $120.4 million | $92.9 million |
| Net loss per share, basic and diluted | $3.78 | $3.93 |
| Cash used in operating activities | $65.1 million | $83.2 million |
| Cash and cash equivalents at year-end | $106.7 million | $86.9 million |
- Operating expenses rose 30%, including a $33.0 million non-cash goodwill impairment in Q4 2022. The impairment followed a sharp share-price decline after interim psoriasis data for izumerogant did not separate from placebo. FY2021 included a $17.25 million 4SC royalty-settlement expense, versus none in FY2022.
- R&D expense increased 17%, principally reflecting higher development costs for the MS trials and izumerogant; lower spending on ulcerative colitis and COVID-19 trials partly offset the increase. G&A expense rose 15%.
- At December 31, 2022, cash and cash equivalents were $106.7 million and other investments were $9.6 million. Current assets totaled $125.9 million versus current liabilities of $13.1 million. Total liabilities were $14.1 million, including operating lease liabilities; the filing reports no conventional borrowings on the balance sheet.
- Stockholders’ equity was $113.7 million, down from $127.1 million, and accumulated deficit was $317.3 million. Financing activities provided $95.8 million, including net proceeds from a $60.0 million private placement and the at-the-market offering. Shares outstanding were 39.3 million at year-end; pre-funded warrants were exercised in January 2023, and 44.4 million shares were outstanding on February 17, 2023.
The company has no meaningful product-sales margin to report and expects continued losses as it advances its pipeline. Management states that year-end cash and investments are expected to fund operations beyond 12 months from issuance of the financial statements; elsewhere, the filing estimates cash runway into the fourth quarter of 2024.
Material operating and development updates
- Vidofludimus calcium — multiple sclerosis: The twin Phase 3 ENSURE trials in relapsing MS and the Phase 2 CALLIPER trial in progressive MS were ongoing. Management expected an ENSURE interim analysis in late 2024 and the first trial’s topline results at the end of 2025; CALLIPER interim data were expected in the second half of 2023 and topline data at the end of 2024. These are forward-looking expectations, not results.
- Vidofludimus calcium — ulcerative colitis: Phase 2 CALDOSE-1 did not meet its primary endpoint, and the overall population showed no meaningful efficacy differences from placebo. The filing describes a possible interaction with concurrent corticosteroid use; further IBD development was not planned without a partner.
- Izumerogant: In the psoriasis Phase 1b interim analysis, active-dose groups did not separate from placebo on PASI reductions at four weeks; the trial continued, with no new safety signal reported. In the mCRPC Phase 1 trial, dose escalation up to 900 mg daily was completed, with no dose-limiting toxicities reported in initial safety data.
- IMU-856: Single- and multiple-dose testing in healthy volunteers was reported as safe and well tolerated, with no maximum tolerated dose reached. A Phase 1 celiac-disease patient study was ongoing; initial results were expected in mid-2023.
- Other notable changes: the investigator-sponsored COVID-19 IONIC trial was closed; the company discontinued its own PSC development program. The company was also exploring options, including potential licensing or a spin-off, for antiviral research activities.
Outlook, risks and unusual items
- Management expects significant expenses and increasing operating losses for the foreseeable future and does not anticipate product revenue in the near term. Additional financing may be needed; equity financing could dilute shareholders, while debt or collaborations could impose restrictions or require rights to be relinquished. No external funding source is committed.
- Clinical outcomes and timelines are uncertain. Key risks include failure of trials or regulatory approval, enrollment and execution delays, dependence on contract research and manufacturing providers, and competition.
- Russia’s invasion of Ukraine disrupted planned trial sites, increased costs and delayed development; the company reported 19 active sites in western Ukraine and anticipated Ukraine would account for approximately 15%–20% of ENSURE enrollment. Inflation and global economic uncertainty may also raise costs or make financing harder.
- The audited financial statements received an unmodified opinion. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end. The auditor identified accrued clinical-trial expense estimation as a critical audit matter, not a qualification of its opinion. The company reported no material litigation.
Key facts for investors to verify
- Whether the stated runway—described both as beyond 12 months and into Q4 2024—remains valid under current trial spending and financing assumptions.
- Progress, enrollment and updated readout timing for ENSURE and CALLIPER, including the impact of Ukraine-related disruptions.
- Further izumerogant psoriasis results and management’s development decision, given the interim lack of separation from placebo and associated goodwill write-off.
- IMU-856 celiac-disease patient data and whether they support advancement beyond Phase 1.
- Actual cash burn, financing capacity and dilution following the 2022 private placement, ATM sales and January 2023 warrant exercises.